POCT stands for point-of-care testing, a category of medical diagnostics performed right where the patient is, whether that’s a doctor’s office, emergency room, pharmacy, or even at home. Instead of drawing blood or collecting a sample and sending it to a central laboratory, POCT delivers results in minutes. The home pregnancy test is one of the most familiar examples, but the category now spans dozens of tests used in hospitals, clinics, and urgent care settings every day.
How POCT Works
The basic idea is simple: a small sample (a drop of blood, a urine specimen, a nasal swab) goes directly into a handheld device or test strip that analyzes it on the spot. Most POCT devices use one of two approaches. Some rely on immunoassays, which detect specific proteins or antibodies tied to a condition. A pregnancy test, for instance, picks up a hormone called hCG in urine. Rapid strep tests and flu tests work the same way, flagging proteins from the virus or bacteria.
Other devices use electrochemical or optical sensors. A blood glucose meter, the most widely used POCT device in the world, measures the electrical signal produced when glucose in a blood drop reacts with an enzyme on the test strip. Newer cartridge-based systems can run multiple tests on a single blood sample, measuring cardiac markers, blood gases, and other values all at once.
Common Types of POCT
- Blood glucose monitoring: Used by people with diabetes at home and by hospital staff to guide insulin dosing.
- Pregnancy tests: Detect hCG in urine within minutes.
- Rapid infectious disease tests: Identify group A strep, mononucleosis, influenza A and B, and COVID-19 using nasal or throat swabs.
- Cardiac marker panels: Measure proteins released during a heart attack, helping emergency physicians make fast triage decisions.
- Blood gas analysis: Checks oxygen, carbon dioxide, and pH levels in critically ill patients, often at the bedside in intensive care.
Speed Compared to Lab Testing
The biggest advantage of POCT is turnaround time. A central laboratory typically takes about 90 minutes to process a routine blood test once the sample arrives, and that doesn’t count transport time. In a randomized controlled trial comparing POCT to standard lab work in an emergency department, the median time from arrival to a clinical decision dropped from 204.5 minutes with lab testing to 106.5 minutes with POCT. That’s nearly half the wait.
A systematic review published in BMJ Open found that general panel tests performed at the point of care led to disposition decisions (whether to admit, refer, or discharge a patient) roughly 40 minutes faster than central lab testing. For patients who ended up being discharged, that translated to about 34 fewer minutes spent in the emergency department. When the tests involved blood chemistry or cell counts specifically, decisions came 74 to 86 minutes sooner. In a busy ED, those minutes add up for every patient in the queue.
Accuracy and Reliability
POCT devices are generally less precise than full-scale laboratory analyzers, but for most clinical purposes they’re accurate enough to guide decisions. The tradeoff depends on the test. Specificity, the ability to correctly rule out a condition, tends to be high across POCT formats. In a study comparing COVID-19 detection methods, both rapid antigen tests and portable PCR devices showed 100% or near-100% specificity.
Sensitivity, the ability to catch true positives, varies more. In that same study, a fluorescent-enhanced rapid antigen test caught about 87% of positive cases, while a portable PCR device caught about 84%. A standard rapid antigen test detected only about 52%. The takeaway: not all point-of-care tests are created equal, and the specific technology inside the device matters a great deal. A negative result on a less sensitive POCT may still warrant follow-up with a lab-based test if symptoms are suspicious.
Regulatory Standards in the U.S.
In the United States, the FDA classifies diagnostic tests into three tiers of complexity: waived, moderate, and high. Most POCT devices fall into the “waived” category, meaning they’re considered simple enough that the risk of a wrong result is very low. Any test approved for home use is automatically classified as waived. To earn that classification, manufacturers must demonstrate that the device is simple to operate, resistant to user error, and performs reliably even under less-than-ideal conditions like temperature swings or slight variations in technique.
Waived tests can legally be performed in settings that hold only a basic Certificate of Waiver, which is why you see rapid strep tests in retail clinics and glucose meters in nursing homes. More complex point-of-care panels, like those analyzing multiple blood values from a single cartridge, may require moderate-complexity certification and trained operators.
Challenges and Limitations
Cost is one of the biggest hurdles. On a per-test basis, POCT is often more expensive than running the same analysis in a high-volume central lab. That cost gap matters because insurance reimbursement for point-of-care tests is inconsistent. In many settings, lack of reimbursement is a major barrier to adoption, forcing hospitals and clinics to justify the investment by showing that faster results reduce overall costs through shorter stays or fewer return visits.
Quality control is another concern. Central laboratories have dedicated staff who calibrate instruments, run daily controls, and troubleshoot failures. When testing moves to the bedside, those quality checks fall on nurses, medical assistants, or patients themselves. Integrating POCT results into electronic health records can also be technically difficult, sometimes requiring manual entry that introduces the risk of transcription errors.
Where POCT Is Heading
The global point-of-care diagnostics market was valued at roughly $21.8 billion in 2025 and is projected to reach about $30 billion by 2033, growing at around 4% per year. Much of that growth is being driven by smartphone-connected devices. Researchers have developed microfluidic chips, essentially miniature labs on a small card, that pair with a phone’s camera to read results. Some systems use the phone to analyze color changes on a test strip, while others attach small sensors or thermal cameras directly to the device.
These smartphone-based platforms make POCT more practical in remote or low-resource settings where laboratory infrastructure doesn’t exist. Advances in nanotechnology and 3D printing are also making it cheaper to manufacture disposable test cartridges, which could eventually close the per-test cost gap with central labs. The long-term trajectory is toward faster, smaller, and more accurate testing that puts diagnostic power directly in patients’ hands.